4Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov 2008; 2: 72-6.
5Miller RG, Costacou T, Orchard TJ. Lipoprotein-associated phos- pholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010; 7: 47-55.
6Wegner M, Araszkiewicz A, Piorunska-Mikolajczak A, Zozulinska- Ziolkiewicz D, Wierusz-Wysocka B, Piorunska-Stolzmann M. Theevaluation of 11_-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem 2009; 42: 1621-7.
7Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Bio12005; 25: 923-31.
8Wang WY, Li J, Yang D, Xu W, Zha RP, Wang YP. OxLDL stimulates lipo- protein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 2010; 85: 845- 52.
9MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife R J, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factoracetylhydrolase, generates two bioactive products during the oxidation of low-density Upoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-87,.
10Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipido12003; 14: 421-30.
